Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
1. A method of removing an antigen from plasma, the method comprising:
administering an antibody to an individual in need of having an antigen removed from the individual's plasma, wherein the antibody binds to the antigen through the antigen-binding domain of the antibody and has a KD(pH5.8)/KD(pH7.4) value, defined as the ratio of KD for the antigen at pH 5.8 and KD for the antigen at pH 7.4, of 40 to 1,000, wherein the antibody binds to the antigen in plasma in vivo and dissociates from the bound antigen under conditions present in an endosome in vivo, and wherein the antibody is a human IgG or a humanized IgG.
2. The method of claim 1 , wherein the antigen is a soluble antigen.
3. The method of claim 1 , wherein the antibody is a humanized IgG.
4. The method of claim 1 , wherein KD is determined using a surface plasmon resonance technique in which the antibody is immobilized, the antigen serves as analyte, and the following conditions are used: 10 mM MES buffer, 0.05% polyoxyethylene sorbitan monolaurate, and 150 mM NaCl at 37° C.
5. The method of claim 1 , wherein the KD(pH5.8)/KD(pH7.4) value is 40 to 400.
6. A method of removing an antigen from plasma, the method comprising:
administering an antibody to an individual in need of having an antigen removed from the individual's plasma, wherein the antibody binds to the antigen through the antigen-binding domain of the antibody and has been determined to have a KD(pH5.8)/KD(pH7.4) value, defined as the ratio of KD for the antigen at pH 5.8 and KD for the antigen at pH 7.4, of 40 to 1,000, wherein the antibody binds to the antigen in plasma in vivo and dissociates from the bound antigen under conditions present in an endosome in vivo, and wherein the antibody is a humanized IgG.
7. The method of claim 6 , wherein the antigen is a soluble antigen.
8. The method of claim 6 , wherein the KD(pH5.8)/KD(pH7.4) value is 40 to 400.
9. A method of removing an antigen from plasma, the method comprising:
administering an antibody to an individual in need of having an antigen removed from the individual's plasma, wherein the antibody binds to the antigen through the antigen-binding domain of the antibody comprising one or more histidine substitutions at one or more heavy chain or light chain variable region positions and has a KD(pH5.8)/KD(pH7.4) value, defined as the ratio of KD for the antigen at pH 5.8 and KD for the antigen at pH 7.4, of 10 to 1,000, wherein the antibody binds to the antigen in plasma in vivo and dissociates from the bound antigen under conditions present in an endosome in vivo, and wherein the antibody is a human IgG or a humanized IgG.
10. The method of claim 9 , wherein the antigen is a soluble antigen.
11. The method of claim 9 , wherein the KD(pH5.8)/KD(pH7.4) value is 10 to 400.
12. The method of claim 9 , wherein the KD(pH5.8)/KD(pH7.4) value is 30 to 400.
13. The method of claim 9 , wherein the KD(pH5.8)/KD(pH7.4) value is 40 to 400.
14. The method of claim 9 , wherein KD is determined using a surface plasmon resonance technique in which the antibody is immobilized, the antigen serves as analyte, and the following conditions are used: 10 mM MES buffer, 0.05% polyoxyethylene sorbitan monolaurate, and 150 mM NaCl at 37° C.
15. The method of claim 6 , wherein KD is determined using a surface plasmon resonance technique in which the antibody is immobilized, the antigen serves as analyte, and the following conditions are used: 10 mM MES buffer, 0.05% polyoxyethylene sorbitan monolaurate, and 150 mM NaCl at 37° C.
16. A method of removing an antigen from plasma, the method comprising administering an antibody to an individual in need of having an antigen removed from the individual's plasma,
wherein the antibody binds to the antigen through the antigen-binding domain of the antibody comprising one or more histidine substitutions at one or more heavy chain or light chain variable region positions and has a KD(pH5.8)/KD(pH7.4) value, defined as the ratio of KD for the antigen at pH 5.8 and KD for the antigen at pH 7.4, of 10 to 1,000,
wherein the antibody binds to the antigen in plasma in vivo and dissociates from the bound antigen under conditions present in an endosome in vivo,
wherein the antibody is a human IgG or a humanized IgG, and
wherein the antibody has been selected by a process comprising:
(i) introducing one or more histidine substitutions at one or more heavy chain or light chain variable region positions of a parent antibody that binds to the antigen through the antigen-binding domain of the antibody; and
(ii) determining the KD of the antibody comprising one or more histidine substitutions at a first pH that is in the range of pH 6.7 to pH 10.0 and at a second pH that is in the range of pH 4.0 to pH 6.5.
17. The method of claim 14 , wherein the antigen is a soluble antigen.
18. The method of claim 14 , wherein the KD(pH5.8)/KD(pH7.4) value is 10 to 400.
19. The method of claim 14 , wherein the KD(pH5.8)/KD(pH7.4) value is 30 to 400.
20. The method of claim 14 , wherein the KD(pH5.8)/KD(pH7.4) value is 40 to 400.
21. The method of claim 14 , wherein KD is determined using a surface plasmon resonance technique in which the antibody is immobilized, the antigen serves as analyte, and the following conditions are used: 10 mM MES buffer, 0.05% polyoxyethylene sorbitan monolaurate, and 150 mM NaCl at 37° C.